BOSTON – March 12, 2012 – Sanjeev Mehta, MD, MPH, has been appointed Director of Quality at Joslin Diabetes Center in Boston, Massachusetts. Joslin is the largest diabetes research and clinical care institution in the world and an affiliate of the Harvard Medical School.

In this new position Dr. Mehta will lead Joslin in developing improvement initiatives aimed at improving health care delivery, health outcomes and cost reduction for individuals with diabetes.

“The ultimate goal of quality in diabetes is to ensure we deliver the best care models for patients so we can help them improve their care and decrease long-term diabetes complications in a cost effective and impactful way,” stated John L. Brooks, President and CEO of Joslin Diabetes Center. “I am delighted that Dr. Mehta is going to lead us in this effort.”

Dr. Mehta joined Joslin in 2007 as an attending physician. He is also an Instructor in Pediatrics at the Harvard Medical School. In addition to pediatric clinical research, Dr. Mehta has been heavily involved in the organization and analysis of the patient data maintained in the Joslin electronic health record (EHR).  He is currently leading the first major redesign of the Joslin EHR in the last 5 years with the goal of creating a more efficient, research-oriented health record.  

With his new position as Director of Quality, Dr. Mehta will focus on his long-standing interest in health services research and quality improvement, expanding his scope to include the Adult Clinics at Joslin.  

Dr Mehta received his medical training at Northwestern University and his pediatric residency training at Cincinnati Children’s Hospital Medical Center. He was a fellow in the combined Joslin Diabetes Center – Children’s Hospital Boston fellowship program in Pediatric Endocrinology.  He also earned a Master in Public Health at the Harvard School of Public Health with a concentration in Clinical Effectiveness. 

Related Articles

A Scientist working in lab
Type 1
Kidney Disease
Research Highlights

The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion

The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion

Three-year clinical trial finds reducing uric acid levels in type 1 diabetes provides no beneficial impact on the progression of diabetic kidney disease BOSTON – (November 8, 2019) – Diabetic kidney...
Read more on The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion
National Diabetes Month
Type 1
Type 2

National Diabetes Awareness Month

National Diabetes Awareness Month

Diabetes is growing at an epidemic rate in the United States and across the globe. According to the Centers for Disease Control and Prevention (CDC), over 30 million Americans have diabetes and 1.5...
Read more on National Diabetes Awareness Month
Red blood cell traveling in an artery
Type 1
Heart Disease
Research Highlights

Research may show way to minimize complications after heart treatment

Research may show way to minimize complications after heart treatment

BOSTON – (October 1, 2019) – People with diabetes are much more likely to develop heart disease than those without the condition. They also are several times more likely to develop complications after...
Read more on Research may show way to minimize complications after heart treatment